Drug treatment of functional dyspepsia

Scandinavian Journal of Gastroenterology

Volumn 26, Issue S182, 1991, Pages 47-60

  Alley, N J T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bismuth; Functional dyspepsia; Prokinetics

Indexed keywords

AMOXICILLIN; ANTACID AGENT; BETHANECHOL; BISMUTH; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; FURAZOLIDONE; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; NITROFURANTOIN; OMEPRAZOLE; ONDANSETRON; PIRENZEPINE; SUCRALFATE; SULPIRIDE;

CONFERENCE PAPER; DROWSINESS; DYSPEPSIA; FUNCTIONAL DISEASE; HUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESTLESSNESS; DRUG EFFECT; GASTRITIS; GASTROINTESTINAL MOTILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; REVIEW;

DYSPEPSIA; GASTRITIS; GASTROINTESTINAL MOTILITY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN;

EID: 0025864084     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529109109537     Document Type: Article

References (115)

1. Nonulcer dyspepsia: potential causes and pathophysiology
2. Management of dyspepsia: report of a working party
3. Identification of subgroups of functional gastrointestinal disorders
4. Heartburn—the acid test
5. Symptoms in gastrooesophageal reflux disease
6. Controlled treatment trials in the irritable bowel syndrome: a critique
7. Prognosis of chronic unexplained dyspepsia. A prospective study of potential predictor variables in patients with endosmotically diagnosed non-ulcer dyspepsia
8. Can gastritis symptoms be evaluated in clinical trials? An overview of treatment of gastritis, non-ulcer dyspepsia and Campylobacter-associated gastritis
9. Gastric and autonomic responses to stress in functional dyspepsia
10. Manometric evaluation of functional upper gut symptoms
11. Controlled trial of metoclopramide in the treatment of flatulent dyspepsia
12. Domperidone in chronic dyspepsia: a pilot open study and a multi centre general practice crossover comparison with metoclopramide and placebo
13. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study
14. Metoclopramide and tardive dyskinesia in the elderly
15. Domperidone
16. Evaluation of the effect of domperidone on human esophageal and gastroduodenal motility by intra-luminal manometry
17. Effects of domperidone on the symptoms of reflux esophagitis
18. Effects of domperidone (R33812) on the motor function of the stomach and small intestine
19. Effects of oral domperidone on gastric emptying and motility
20. Chronic dyspepsia: double-blind treatment with domperidone (R33812) or a placebo. A multi-centre therapeutic evaluation
21. Domperidone in the treatment of dyspepsia: a double-blind placebo-controlled study
22. Oral domperidone in chronic postprandial dyspepsia. A double-blind placebo-controlled evaluation
23. A double-blind study of domperidone in the symptomatic treatment of chronic postprandial upper gastrointestinal distress
24. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying
25. A double-blind crossover trial of domperidone in chronic postprandial dyspepsia
26. Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress
27. Double-blind evaluation of domperidone in acute vomiting and dyspeptic disorders
28. Clinical trial on the effect of domperidone on non-ulcer dyspepsia
29. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study
30. Sulpiride improves functional dyspepsia: a double-blind controlled study
31. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders
32. Cisapride restores the decreased lower oeso-phageal sphincter pressure in reflux patients
33. Effect of c, a new prokinetic agent, on esophageal motor function
34. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and post-pyramidal motor activity of the distal esophagus in man
35. Effects of cisapride on gastrointestinal transit in healthy humans
36. Impaired transit of chyme in chronic intestinal pseudo-obstruction. Correction by cisapride
37. Effect of cisapride on gastric and oesophageal emptying in insulin-dependent diabetes mellitus
38. Effect of cisapride on gastric emptying of indigestible solids in patients with gahtroparesis diabeticorum. A comparison with metoclopramide and placebo
39. Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients
40. Stimulation of gastroduodenal motor activity: cccand cholinergic modulation
41. 2 receptors
42. Effect of the non-antidopaminergic drug cisapride on postprandial nausca
43. Non-cholinergic. non-antidopaminergic treatment of chronic digestive symptoms suggestive of a motility disorder: a two-step pilot evaluation of ciqridc
44. Control of reflux symptoms in hiatal-hernia patients through stimulation of gastric ocsophageal motility with cisapride
45. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial
46. Dose rcsponse study of eisapride in the management of non-ulcer dyspepsia
47. Clinical evaluation of cisapride in postprandial dyspepsia
48. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis
49. Van DeMierop L. Cisapride in the treatment of chronic functional dyspepsia. Results of a double-blind, placebo controlled, crossover study
50. Non-ulcer dyspepsia. Effect of the gastrointestinal prokinetic drug cisapride
51. Efficacy of cisapride in patients with non-ulcer dyspepsia. A placebo-controlled study
52. Therapy of chronic functional dyspepsia: multicenter crossover study of cisapride and placebo
53. Comparative effects of oral cisapride and metoclopramide on gastric emptying of solids and symptoms in patients with functional dyspepsia and gastroparesis
54. Treatment of chronic dyspepsia with eisapride and domperi-done
55. Symptomatic radionuclide and therapeutic assessment of chronic idiopathic dyspepsia: a double-blind placebo-controlled evaluation of cisapride
56. Relief of epigastric pain in non-ulcer dyspepsia: controlled trial of the promotility drug cisapride
57. Cisapride in the treatment of non-ulcer dyspepsia patients, unresponsive to domperidone or metoclopramide: a multi centre, double-blind, placebo-controlled study [Abstract]
58. Two kinds of tryptamine receptor
59. 3H]spiroperidol
60. A non classical 5–hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system
61. 3 receptors in rat brain using radioligand binding
62. Blockage of serotonin receptors on autonomic neurones by (-)-cocaine and some related compounds
63. Neuronal 5–HT receptors in the periphery
64. Identification of serotonin M-receptor subtypes and their specific blockage by a new class of drugs
65. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis
66. 3 receptor antagonist, in the rat and cynomolgus monkey
67. 3 receptor antagonist) on gastric emptying of a solid meal in normal subjects
68. Mouth-to-cecum transit time in man is reduced by a novel serotonin M-receptor antagonist [Abstract]
69. 3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides
70. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5–hydroxytryptamine receptor (type 3) antagonist
71. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog
72. 125I-motilin to duodenal muscle
73. Improvement of gastric emptying in diabetic gastro-paresis by erythromycin. Preliminary studies
74. Prokinetic agents: a key in the future of gastroenterology
75. Stimulation of incompetent lower esophageal sphincter. A possible advantage in therapy of chronic heartburn
76. Comparative effects of metodopramide and hethanechol on lower esophageal sphincter pressure in reflux patients
77. Cholinergic effects on esophageal transit and clearance
78. Force-velocity characteristics of esophageal muscle: effect of acetylcholine and nor epinephrine
79. Review of the current status of prokinetic agents in gastroenterology
80. Comparison of dicyclomine with antacids and without antacids in dyspepsia
81. Trimebutine, a new antispasmodic in the treatment of dyspepsia
82. Dicyclomine for idiopathic dyspepsia
83. Ukaraktäristisk dyspepsi i almen praksis. En kontrolleret undersøgelse med et antacidum (Aliminoxè)
84. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia
85. Treatment with cimetidine, antacid or placebo in patients with dyspepsia of unknown origin
86. Low-dose antacids and pirenzepine in the treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A randomized, double-blind, placebo-controlled trial
87. The treatment of non-ulcer dyspepsia
88. Cimitidinebehandling of røntgennegativ dyspepsi
89. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia
90. A controlled trial of cimetidine for the treatment of non-ulcer dyspepsia
91. Non-ulcer dyspepsia in Nigerians clinical and therapeutic results
92. Cimetidine in the management of symptomatic patients with duodenitis. A double-blind controlled trial
93. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes
94. Symptomatic treatment of non-ulcer dyspepsia with cimetidine
95. Randomized. double-blind. placebo-controlled crossover trial of cimetidine and pirenzepine in non-ulcer dyspepsia
96. Cimetidine responders in non-ulcer dyspepsia
97. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study
98. Dyspepsia: incidence of non-ulcer disease in a controlled trial of ranitidine in general practice
99. Pirenzepine in non-ulcer dyspepsia. A double-blind, placebo controlled trial
100. Effect of pirenzepine in the treatment of non-ulcer dyspepsia. A double-blind study
101. Truncal vagotomy and drainage in the treatment of ulcer-like dyspepsia without ulcer
102. Proxrmal vagotomy in dyspeptic patients without an ulcer
103. Sucralf ate versus placebo in treatment of non-ulcer dyspepsia
104. Controlled clinical trial with sucralfate in the treatment of macroscopic gastritis
105. Is Helicobacter pylori a cause of nonulcer dyspepsia?
106. Campylobacter pyloridis and associated gastritis: investigator blind, placebo-controlled trial of bismuth salicylate and erythromycin ethyl-succinate
107. Role of Campylobacter pyloridis in non-ulcer dyspepsia - a randomized controlled trial [Abstract]
108. Non-ulcer dyspepsia and short-term De-Nol therapy: A placebo-controlled trial with particular reference to the role of Campylobacter pylori
109. Double-blind trial of De-Nol in non-ulcer dyspepsia associated with Campylobacter pyloridis gastritis [Abstract]
110. Campylobacter-associated gastritis in patients with non-ulcer dyspepsia: a double-blind, placebo-controlled trial with colloidal bismuth sub citrate
111. Effect of colloidal bismuth sub citrate on symptoms and gastric histology in non-ulcer dyspepsia. A double-blind, placebo-controlled study
112. Campylobacter pylori-associated gastritis: A double-blind placebo-controlled trial with amoxycillin
113. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori
114. Triple therapy for Helicobacter pylori in non-ulcer dyspepsia
115. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled trials